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1. Introduction  
There are a number of inherited predispositions to colorectal cancer (CRC) which can be 
broadly categorized into two groups; those with associated polyposis, such as familial 
adenomatous polyposis and the hamartomatous polyposis syndromes; and those that are 
linked to the non-polyposis syndromes, such as hereditary non polyposis colorectal cancer 
(HNPCC). The genetic basis of both the polyposis and non-polyposis syndromes are 
reflected in the CRC population who have no apparent family history of disease. 
Approximately 80% of all cases of CRC are associated with chromosomal instability [1] and 
are likely to have mutations in the Adenomatous Polyposis Coli (APC) gene whereas the 
remaining 20% with microsatellite instability appears to be due primarily to epigenetic 
inactivation of the DNA mismatch repair (MMR) gene MLH1 [2]. 
The disease HNPCC accounts for somewhere between 2% and 5% of all CRCs diagnosed 
and is associated with a younger age of disease onset compared to the general population 
[3,4]. HNPCC is a disease by definition based on the Amsterdam Criteria where there need 
to be three cases of CRC, one of which must be diagnosed under the age of 50 years, one 
patient must be a first degree relative of the other two, span two generations and familial 
adenomatous polyposis should be excluded [5]. Modification of the Amsterdam Criteria has 
been ongoing since its original inception due to an increasing awareness of what constitutes 
this disease. HNPCC used to be known as either the Cancer Family Syndrome or Lynch 
Syndrome [6]. It is now accepted that families where a mutation in the DNA mismatch 
repair genes (MMR) MSH2, MLH1, MSH6 or PMS2 has been identified are now termed 
Lynch Syndrome families whereas those with no mutation are termed HNPCC [7].  The 
primary function of MMR genes is to eliminate base-base mismatches and insertion-deletion 
loops which arise as a consequence of DNA polymerase slippage during DNA replication 
[8]. MMR confers several genetic stabilisation functions; it corrects DNA biosynthesis errors, 
ensures the fidelity of genetic recombination and participates in the earliest steps of cell 
cycle checkpoint control and apoptotic responses [9,10]. MMR gene defects increases the risk 
of malignant transformation of cells, which ultimately results in the disruption of one or 
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several genes associated with epithelial integrity. The identification of germline mutations in 
families with Lynch Syndrome accounts for only ~50% of all families that fulfil the clinical 
diagnosis defined by the Amsterdam criteria [11]. The remaining families have no 
identifiable genetic predisposition yet fulfil the diagnostic criteria for the disease and are 
referred to as HNPCC families. 
DNA MMR is a housekeeping function of all nucleated cells and as such any breakdown in 
the fidelity of this process is likely to result in disease irrespective of which gene is affected. 
Unlike other predispositions to colorectal cancer such as familial adenomatous polyposis, 
there are no obvious genotype/phenotype correlations in Lynch syndrome. Mutations that 
result in the loss of MSH2 or MLH1 irrespective of where they occur in the respective gene 
alter the risk of developing malignancy. Furthermore, mutations in DNA MMR genes do not 
predict a phenotype since any breakdown in the fidelity of this process results in a “mutator 
phenotype”.  It has been obvious from the first MSH2 and MLH1 mutation reports that 
differences in the ages of cancer diagnosis in patients harbouring germline mutations in 
DNA MMR genes do occur both within and between families. Furthermore, unrelated 
families harbouring the same mutation present with different disease profiles as do patients 
from within the same family [12-14]. The differences in disease expression both within and 
between families harbouring the same mutation are most likely a result of environmental, 
genetic or a mixture of both influences.  
Identification of environmental factors that could account for differences in the age of 
colorectal cancer diagnosis of Lynch Syndrome is almost intractable when undertaken as a 
retrospective study and is best undertaken prospectively to include as many environmental 
variables as possible. Notwithstanding, knowledge about environmental factors and disease 
risk in Lynch Syndrome is important and studies are required to identify those which 
protect or promote disease. 
Conversely, as genetic factors can be assessed after the fact they lend themselves more 
readily to retrospective interrogation and consequently identification. Identifying genetic 
factors that could explain differential disease expression in Lynch syndrome is now 
achievable due to the development of appropriate technology that allows for the rapid 
screening of large numbers of patients in conjunction with the accumulation of large cohorts 
of patients that allow for robust statistical analysis.  
The search for modifier genes has been ongoing ever since the first groups of Lynch 
syndrome families were identified. Initial studies focused on genes associated with 
xenobiotic metabolism which have been followed by genes involved in the immune 
response, DNA repair, cell cycle control and as yet undefined genomic regions identified as 
a result of large genome wide association studies searching for genetic risk factors for 
colorectal cancer. This review will focus on “modifiable” (those that can be altered by 
manipulation) candidate modifier genes and those that have been chosen as a result of 
biological plausibility (which may or may not be modifiable), as shown in Table 1. 
Biological plausibility and pathways of published “positive” results have been questioned 
[15], indicating that the functional significance of single nucleotide polymorphisms (SNPs) 
should be known before they are linked to disease [16]. A few published reports linking 
SNPs without known functional significance [17,18] or studies have failed to confirm a 
reported associations [19]. Known genetic variation has significantly impacted on the early 
detection and diagnosis of inherited cancer [20, 21], indicating that the search for genetic 
variation in cancer should continue.  
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Modifier Genes and polymorphisms studied in Lynch Syndrome 
Candidate Genes Type of 
Polymorphisms 
Effect Publication 
indicating 
association or not 
IGF1 CA-repeat promoter function [22, 23]
MTHFR SNP enzyme activity [24]
HFE SNP protein function [25]
NAT2 SNP enzyme activity [26, 27]
GSTM1 null allele enzyme activity [26, 27]
GSTT1 null allele enzyme activity [26, 27]
ATM SNP protein function [28]
IL6 SNP cytokine activity [29]
IL4 SNP cytokine activity [29]
IL1 SNP receptor binding  
IL10 SNP cytokine activity [29]
IL1Rn SNP null receptor [29]
TNF- SNP cytokine activity  
IFN- SNP cytokine activity  
TP53 SNP protein function [32, 39, 40] 
MDM2 SNP promoter function [42]
Aurora-A SNP protein function [44, 45, 48] 
Cyclin D1 SNP protein function [44, 45, 48] 
Table. 1. Candidate modifier genes and their respective types of polymorphism that have 
been studied in cohorts of Lynch syndrome patients.   
2. Cell cycle control gene polymorphisms: TP53. MDM2, Aurora-A and 
CyclinD1 
The TP53 gene isa tumour suppressor gene that regulates the transcription of genes 
necessary for the maintenance of genomic integrity by blocking cell proliferation after DNA 
damage and initiating apoptosis if it is too extensive [30, 31]. In 2004 the R72P 
polymorphism in TP53 was found to be associated with age of diagnosis of colorectal cancer 
(CRC) in an American Lynch syndrome study [32]. The R72P SNP in TP53 has been shown 
to result in two forms of the protein, which are not functionally equivalent [33, 34], and has 
been widely studied in a variety of malignancies [35 - 38]. Subsequent studies, including one 
Finnish and a collaborative Australian and Polish study, of the TP53 polymorphism and age 
of diagnosis of CRC in Lynch syndrome failed to confirm the reported association [39, 40]. 
The lack of an association was suggested to be related to a polymorphism in MDM2, which 
results in increased levels of MDM2 that culminates in the inability to properly stabilise 
TP53’s response to cellular stress [40]. Evidence supporting this notion in HNPCC however, 
could not be found in other studies [39, 41]. The failure to corroborate the role of TP53 as a 
modifier gene between the different studies could be due to differences in the mutation 
spectrum of the various study populations; number of relatives included, population 
stratification and/or type 1 statistical error. Population stratification is unlikely to account 
for differences between the study populations as it has been shown that for most of the 
common disease associated polymorphisms, ethnicity is likely to be a poor predictor of an 
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individuals’ genotype [43]. Type 1 statistical error seems to be the most likely explanation 
since the population sizes differ significantly in size with a range between 86 cases through 
to a maximum number of 220. In the larger studies reported to date (encompassing 193 and 
220 patients, respectively), no association was observed thereby providing evidence against 
an association. 
Aurora-A and Cyclin D1, genes both involved in cell cycle control, have also been associated 
with the age of onset of CRC in Lynch syndrome patients from North America [44, 45]. After 
the initial studies suggesting Aurora-A polymorphisms were linked to the average age of 
disease diagnosis follow-up reports in larger patient populations consistently failed to 
replicate this finding.  In contrast, studies of Cyclin D1 polymorphisms and their association 
with the age of disease onset in Lynch syndrome resulted in contradictory results when 
studied in populations from North America, Germany, Finland and a combined study of 
Australian and Polish patients [44, 46 – 48]. A potential explanation for the association 
between Cyclin D1 and hMSH2 mutation carriers observed in the Australian and Polish 
Lynch syndrome patients was the relative paucity of MSH2 mutation carriers in the German 
and Finnish populations [47]. With the expansion of the study population from the 
Australian/Polish patient cohort the original report of an association with Cyclin D1 could 
not be replicated (See Fig. 1). In conclusion, the evidence now suggests that there is no 
association between Cyclin D1, MSH2 and disease risk in Lynch syndrome, such that overall 
Cyclin D1 does not appear to be associated with the age of disease diagnosis. 
 
 
Fig. 1. Kaplan-Meier analysis of Cyclin D1 polymorphism and the age of disease onset in 
Australian and Polish Lynch syndrome patients.  276 MSH2 mutation positive patients were 
included in this study of which 107 were diagnosed with colorectal cancer. Log-rank, 
Wilcoxon and Tarone-Ware tests were not significant. 
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3. Xenobiotic clearance gene polymorphisms: NAT1, NAT2, GST, CYP1A1 
Genes involved in xenobiotic metabolism, which include N-acetyl transferase 1 (NAT1), N-
acetyl transferase 2 (NAT2), glutathione-S-transferase (GST) and cytochrome P450, have the 
ability to influence an individual’s susceptibility to environmental and occupational 
carcinogens and predisposition to cancer [49]. The detoxification and elimination of foreign 
chemicals is controlled by complex mechanisms involving phase I enzymes that include 
cytochrome P450, and phase II enzymes such as GSTs and NATs [50]. Because of the 
significance of xenobiotics in the environment, perturbations in the ability to remove them 
are likely to alter disease risk. Polymorphisms in the genes mentioned above have been 
associated with colorectal cancer but the roles that the different SNPs have on cancer risk are 
controversial [26, 27, 51 – 61].  
In 1999 an association between polymorphisms in NAT2 and the age of diagnosis of CRC in 
Lynch syndrome patients was reported, and the association was later replicated in a second 
independent report [26, 54]. Both studies had relatively small sample sizes (78 and 86 cases). 
Re-investigation of the association in a smaller study (69 cases) and a more appropriately 
sized one (220 cases) failed to confirm the association [58, 26]. The failure to confirm the 
association could be due to population stratification, but this is unlikely since if there is a 
functional difference in the gene in question,so its effects should be observed in all subjects, 
although not necessarily statistically significant in all populations. The most likely 
explanation for the failure to replicate initial findings is the small study population sizes that 
were used in assessing the potential association. This is further confirmed in a review by 
Brockton et al. 2000 [62] concluding that in 10 of 11 studies of invasive CRC and NAT2 
acetylator genotype, no association was observed.  
Similar results are reported for the polymorphisms in GST and cytochrome p450 genes 
and Lynch syndrome. Several research groups reported an association, while others failed 
to confirm them [25, 26, 51, 52, 53, 53, 63]. In on study the Msp1 wildtype allele of 
cytochrome P450 1A1 gene (CYP1A1) was associated with a decreased risk of CRC [26] 
which could have been due to it not being in Hardy-Weinberg equilibrium. The 
identification of an allele that is not in Hardy-Weinberg equilibrium suggests that either a 
genotyping error has occurred thereby skewing the results or it can be  
taken as supporting evidence for a correlation with disease [64]. The CYP1A1 gene has 
previously been associated with CRC and two SNPs in the CYP1A1 gene have been 
associated with CRC [65], which taken together with the report of Talseth et al. 2006 [26] 
supports the notion that variation in this gene is involved in the some aspect of CRC 
development.  
Studies examining variation in xenobiotic clearance are likely to be subject to strong 
environmental influence and this is supported by findings from different countries. Studies 
examining patients of European descent for polymorphisms in GST genes seems to find no 
obvious relationship between the SNPs and cancer risk, while a study from Korea reports an 
association [25, 26, 63]. Taken together, these results suggest a complex relationship between 
the environment and individual genotypes that add to other more obvious problems 
associated with searching for modifier genes. Additional studies are required to determine 
the relationship between GST and CYP1A1 polymorphisms and disease risk in Lynch 
syndrome.  
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4. Immune response gene polymorphisms: IL6, IL4, IL1IL10, IL1Rn,  
TNF-IFN- 
Cytokine mediated events may play a role in tumour development within inflammatory 
cells by producing an environment that supports tumour growth by promoting 
angiogenesis and facilitating genomic instability. The quintessential example is that of 
Crohn’s disease where there is an increased risk of developing CRC if left untreated [66]. 
Inflammatory responses can also increase DNA damage, growth stimulation and enhanced 
survival of damaged cells [66, 67]. SNPs in cytokine genes can have an effect on the 
transcription levels of the respective genes and resulting in differences in both pro- and anti-
inflammatory response activity. A series of polymorphisms in a number of cytokines has 
been investigated in relation to CRC risk and other cancer types but not for Lynch syndrome 
[68 – 77]. In addition, genetic variation in pro- and anti-inflammatory cytokine genes has 
been shown to influence individual response to carcinogen exposure [69], but no association 
has been identified in the one report focusing on a series of SNPs in cytokine genes and 
disease expression in Lynch syndrome [28]. Given the complexity of the inflammatory 
response and the limited number of SNPs utilised in that study, it cannot be ruled out that a 
relationship between SNPs influencing the immune response and Lynch syndrome exits.  
5. Insulin like Growth Factor IGF-1 Gene polymorphisms 
The IGF-1 gene was first reported as a potential modifying gene in Lynch syndrome disease 
expression in 2006. The CA-repeat polymorphism located near the IGF-1 promoter region was 
described as having an association with the age of disease onset in a cohort of 121 Lynch 
syndrome patients originating from the United States [22]. Certainly this is not the first time 
that a repeat region has been implicated in disease; with numerous studies reporting a link 
between DNA repeat regions significantly altering risk of prostate cancer [78 – 80] breast 
cancer, squamous cell carcinoma, bladder and lung cancers [81 – 84]. DNA microsatellite 
repeat regions are also strongly associated with Lynch Syndrome by virtue of their instability 
in tumours which is a consequence of the loss in the fidelity of DNA MMR [8].  
IGF-1 is important for cellular proliferation and differentiation however, elevated levels of 
IGF-1 have been reported to have significant links to diseases such as CRC which is thought 
to be a result of the mitogenic and anti-apoptotic effects elicited by this protein [22, 85]. 
Several environmental and physiological reasons have been proposed that influence IGF-1 
expression; however there is now evidence to suggest that a genetic role is significant. Rosen 
et al. was the first to report that the length of the CA repeat region in IGF-1 may be 
associated with circulating IGF-1 levels [86]. In a similar growth factor related gene, 
Epidermal Growth Factor Receptor (EGFR), a CA repeat region is located in intron 1. A 
study of this EGFR polymorphic repeat region revealed lower transcriptional activity with 
increasing numbers of polymorphic CA repeats coinciding with lower levels of gene 
expression [87]. In 2007, a similar result was reported for the IGF-1 gene in swine where the 
length of the CA repeat region was clearly associated with circulating levels of IGF-1 [88]. 
More recently, additional human data has been published which supports the notion that 
this polymorphism is linked to serum levels of IGF-1 [89]. From this data a trend is 
emerging that CA repeat polymorphisms in growth factor related genes, such as IGF-1, are 
related to overall gene expression, which is reflected in the circulating serum levels of the 
respective proteins. Accumulating evidence suggests that serum IGF-1 levels appear to be 
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linked to disease with recent reports indicating that elevated levels of IGF-1 are observed in 
breast, prostate and CRC [90 – 93]. There have been estimates that higher circulating levels 
of IGF-1 result in a 15% increase in the risk of developing disease, insinuating the 
importance of circulating IGF-1 in disease progression [94].  
As CRC involves the accrual of a number of specific molecular alterations [95, 96], 
consistently high IGF-1 serum levels may increase cellular proliferation, thereby enhancing 
the rate by which genetic alterations accumulate. Both normal colonic epithelial and 
transformed cells are IGF-1 responsive; thus, IGF-1 can influence not only the likelihood of 
disease initiation but also disease progression. This overall process provides some insight 
into how intracellular serum levels of IGF-1 may have a significant influence in accelerating 
the accumulation of genetic errors leading to disease, especially in persons who have 
inherited a predisposition to develop malignancy characterized by a mutator phenotype as 
observed in Lynch syndrome.  
An equally important facet to disease risk as a result of increased levels of IGF-1 is its link 
with obesity. Obesity and physical inactivity are strong independent determinants of insulin 
resistance and hyperinsulinaemia [97 – 104] and this is associated with an increased risk of 
CRC [101, 102]. Increased blood insulin lowers IGF-1 binding protein levels, which often 
results in an increase of free IGF-1 [105]. As IGF-1 is associated with both percentage body 
fat and general overall obesity [106], an increased level of IGF-1 expression as a result of 
shorter CA repeat lengths may have an enhanced effect in persons who are obese where 
IGF-1 serum levels are already elevated.  
In addition to the IGF-1 effect, CRC risk is also increased in obese patients through oxidative 
stress in adipose tissue. This is caused by increased lipid peroxidation leading to the 
production of reactive oxygen species. In regards to cancer, reactive oxygen species can 
damage DNA by several methods including DNA base modification, deletions, frame shifts, 
strand breaks, DNA-protein cross-links, and chromosomal rearrangements [107]. Both lipid 
peroxidation and increased DNA damage are likely to promote tumour development by 
generating reactive oxygen species, increasing hormone production/bioavailability of IGF-1 
and providing an energy-rich environment. This combined mechanism is potentially a risk 
factor for all types of CRC, however in Lynch syndrome this may be of greater significance 
in a deficient DNA repair environment where enhanced levels of IGF-1 inhibit cell death 
and encourage cellular proliferation. Together, the relationship between obesity and IGF-1 
CA repeat length may be of particular importance in obese Lynch syndrome cases as these 
may be at greatest risk of developing disease at a younger age.  
The role of inherited factors in circulating IGF1 serum levels is likely to be substantial with 
estimates of the proportion of variance in IGF-1 that is genetically determined varying 
somewhere between 38% to over 80% [108]. A substantial amount of data has been reported 
revealing differences in IGF levels across ethnic groups [109 – 111], however this is 
suggestive of dietary and lifestyle factors having a more modifiable effect on serum levels 
when combined with genetic ancestry. One such study has shown that the impact of several 
nutritional factors such as calcium, dairy products and vegetables on IGF1 levels is quite 
different in racially stratified models as reported between African-American and European 
American males [112]. This is strongly suggestive of there being population differences that 
differentially modify the effect of several nutrients on IGF levels. Together this information 
is suggestive that environmental factors such as calorific intake, lifestyle and demographic 
factors are probably playing a substantial role in ethnic variation in disease risk in regards to 
www.intechopen.com
 
Colorectal Cancer Biology – From Genes to Tumor 
 
44
serum IGF levels. This is intriguing as it may also be contributing to the differences in 
relative disease risk observed between the Polish and Australian cohorts as reported [22]. 
The data reported to date [21] indicate a significant interaction between the CA repeat 
polymorphism length and disease expression in Lynch syndrome which is likely to be 
linked to circulating levels of IGF-1. The data suggest a significant correlation for earlier 
onset CRC in participants who carry 17 or less IGF-1 CA repeats in over 400 Lynch 
syndrome patients. An encouraging aspect of the results of this study is that significance is 
retained across two different populations where variance in IGF-1 allele size frequencies 
occur [22]. A limitation however in defining the exact relationship between IGF-1 expression 
and cancer incidence in Lynch syndrome patients is the genotype–phenotype correlation 
between the IGF-1 CA-repeat number and the corresponding serum levels. Assessment of 
serum IGF-1 concentration, however, has the inherent problem of serum IGF-I 
measurement, which is typically assessed at only one time point yet for accurate analysis 
should be performed multiple times from any single patient. Whether it would be feasible to 
monitor IGF-1 serum levels in families with Lynch syndrome is an area which needs further 
investigation. Future work should also include additional candidate polymorphisms located 
within IGF-1 or IGFBP-3 that interact with the IGF-1 pathway and may provide further 
insight into the overall IGF-1 effect. At present, however the IGF-1 pathway remains largely 
under-investigated, and there is now a requirement for further work to develop a more 
thorough understanding of the relationship between IGF-1 genotype, expression and its 
implication in disease risk.  
6. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms 
There have been tantalizing reports in the literature that polymorphisms in the MTHFR gene 
are associated with altered CRC risk. These polymorphisms occur in relatively high 
frequency in the general population and the two that promote special attention are both 
associated with altered enzymatic function. MTHFR is a key folate-metabolizing enzyme 
involved in both DNA methylation and DNA synthesis. The enzyme catalyses the 
irreversible conversion of 5,10-methylenetetrahydrofolate (5,10-MTHF), needed for purine 
and thymidine synthesis, to 5-methyltetrahydrofolate (5-MTHF), which is necessary for 
methionine production. Insufficient thymidine results in uracil misincorporation into DNA, 
leading to single-strand and double-strand breaks. This can increase the incidence of DNA 
damage, thereby increasing the risk of genetic instability. The understanding that folate 
metabolism can both equally influence DNA synthesis and methylation has made the study 
of environmental and genetic variants associated with MTHFR particularly attractive as a 
candidate genetic factor that influences cancer susceptibility. Two common polymorphisms, 
C677T and A1298C are located within the MTHFR gene and have been linked to altering the 
function of the encoded protein. This has lead to these variants being the focus of numerous 
studies into CRC risk outside the context of an inherited predisposition to disease. Both 
polymorphisms result in a substitution of an amino acid and have previously been shown to 
significantly influence MTHFR enzyme activity [113]. C677T is located within the coding 
region for the catalytic domain, resulting in an amino acid substitution from alanine to 
valine that is associated with a reduction of enzyme activity. The A1298C polymorphism, 
located in the regulatory region of MTHFR, substitutes an amino acid change from 
glutamine to alanine. Evidence suggests that A1298C also reduces MTHFR activity, however 
it is reported to be less influential than C677T [114]. This modifying effect incurred by the 
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presence of one or both polymorphisms in a pivotal folate metabolism pathway and its 
association with sporadic disease suggests that these polymorphisms are of particular 
interest with respect to modifying disease risk in Lynch syndrome.   
Both A1298C and C677T are in strong linkage disequilibrium with no evidence of the 
existence of a MTHFR allele that carries both the homozygote (C1298C/T677T) variants of 
these polymorphisms [115 – 117]. Owing to this linkage disequilibrium, no studies have 
been reported where patients have inherited both homozygote variants. Nevertheless, 
heterozygote carriers of 1298C and 677T have been reported. The effect of inheriting both 
alleles in trans (i.e. one allele with the 677T polymorphism and the other with the 1298C 
polymorphism) effectively reduces overall MTHFR activity, thereby significantly altering 
the kinetics of folate metabolism. Data reported from an Australian and Polish study on the 
effects of MTHFR variants and disease expression in Lynch syndrome revealed that 
heterozygote forms of the MTHFR variants were required for a significant protective effect 
to occur [23]. The Kaplan-Meier survival estimates reported in this study predicted a 
median age gap of 10 years later for CRC onset in patients carrying the combined 
heterozygote MTHFR genotype which was supported by multi variable regression 
modelling statistics. The data also suggested this effect was significant in both hMLH1 and 
hMSH2 carriers, where previously only a significant association had been described in 
hMLH1 for C677T only [118]. The most likely cause for this discrepancy between the 
Australian/Polish study and those by reported by Pande et al (2007) [119] is likely to be due 
to a type 1 statistical error as the reported association in hMLH1 carriers were in a 
considerable smaller sample size, although differences in the ethnicity of Lynch syndrome 
cohorts cannot be ruled out as a contributing factor.  
The mechanism by which C677T and A1298C appears to influence disease risk can be 
explained by the functional effects that these polymorphisms have on MTHFR and 
consequently folate metabolism. Previous reports have demonstrated a reduction of up to 
60% in the activity of MTHFR when both C677T and A1298C heterozygote alleles were 
present in the gene. The reduction of MTHFR activity leads to an increased concentration of 
its substrate 5,10-MTHF. The increased pool of 5,10-MTHF pushes folate metabolism 
towards DNA synthesis, in turn reducing the pool of uracil. A reduced quantity of uracil 
potentially reduces the overall risk of uracil misincorporation as a result of its limited 
availability. For individuals with a MMR deficiency, the effect of reduced MTHFR enzyme 
activity may be advantageous since uracil misincorporation could be particularly 
deleterious in conjunction with an impaired DNA repair pathway. The subsequent lower 
levels of 5-MTHF may also be beneficial due to a potential reduction in DNA methylation. 
Hypermethylation of the promoter of tumour suppressor or MMR genes may lead to gene 
silencing, therefore a reduction in methylation through decreased MTHFR activity could 
lead to lower probability of this type of gene silencing occurring.  
Numerous case control and cohort studies have investigated the relationship between folate 
intake and CRC risk with the majority reporting a reduction in CRC incidence with higher 
levels of folate [116]. The outcome of one meta-analysis suggested that CRC risk could be 
reduced by up to 25% with a high level of dietary folate compared to a low level one [117]. 
Further studies are required to clarify to what extent total folate has on disease risk; 
however it is generally accepted that there is an association and that a number of common 
genetic variants alter either the cellular levels or functioning of folate metabolism enzymes 
and are likely to have an important role in determining an individual’s response to changes 
in dietary folate. With this in mind further studies into functional polymorphisms in the 
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folate metabolism pathway would benefit significantly by including total folate levels so 
that a more exact assessment its role could be made. Using this approach a more precise 
view of the relationship between folate intake and disease risk may become apparent where 
Lynch syndrome patients could be stratified by MTHFR genotype. Accurately estimating 
dietary folate intake however may prove difficult and therefore the analysis of plasma folate 
levels may be a more viable alternative. Future studies would benefit by including other 
dietary factors including alcohol, choline, and methionine intake which are known to effect 
folate metabolism besides folate and folic acid [119]. An accurate level of plasma folate 
combined with MTHFR C677T and A1298C genotypes is an interesting prospect and may 
provide an indicator of individual risk of developing a Lynch syndrome related CRC.  
The identification of MTHFR polymorphisms being associated with divergence in disease 
risk in Lynch syndrome provides the basis for targeted intervention measures that could be 
used to reduce the risk of disease development. Dietary supplementation of folate/folic acid 
in Lynch syndrome families may prove to be beneficial in decreasing disease risk or 
prolonging the time before the diagnosis of malignancy. Dietary supplementation and a 
change in disease risk however, are more complex than previously thought. Folic acid 
supplementation has been proven to be beneficial in decreasing neural tube defects (NTD’s), 
[120] and was the catalyst for the United States and Canada introducing the compulsory 
supplementation of folic acid in flour in 1996 with the aim to reduce the incidence of NTD’s. 
Despite proving successful for this purpose an unexpected trend was observed in both 
countries as described by Mason et al. (2007) [121] who investigated the relationship 
between the onset of folic acid fortification and rises in the incidence of CRC. This analysis 
indicated that in the early part of the 1990’s the age-adjusted incidence of CRC had declined 
gradually in both countries. Between 1995 and 1996 however, the incidence rate in the 
United States showed a slight increase followed by more marked increases in 1997 and 1998. 
A similar finding was observed in the Canadian population, which also corresponded to the 
mandatory supplementation of folic acid. In both populations the increase in CRC incidence 
was highly significant when compared to pre-existing trends in both men and women. 
These observations have lead to a hypothesis that mandatory folic acid supplementation 
was responsible for the spike in CRC rates which after peaking approximately 2-3 years 
after its introduction have begun to decline once again [121].  
The association of increased CRC incidence with folate supplementation has been supported 
by the results of two large-scale studies which have recently emerged from both the United 
States and United Kingdom. In both these phase III studies a common trend was observed 
in participants who supplemented their diets for three years with a daily dose of 1000ug and 
500ug folic acid respectively, and an increased risk of developing a colorectal adenoma, with 
the greater risk in those participants consuming the higher 1000ug dose [122, 123]. Studies in 
mismatch repair or tumour suppressor gene deficient mice have demonstrated that the 
timing of folate supplementation is important in the association it may have on disease risk. 
In the first few months of folate supplementation a threefold decrease in colorectal 
adenomas has been observed when compared to mice with a moderate folate deficient diet. 
Dietary folate treatment after the development of carcinomas had the opposite effect 
however, with folate deficiency significantly decreasing the number of adenomas compared 
with supplementation [124, 125]. Together, this evidence suggests that as long as an 
individual is healthy, folate supplementation is protective whereas if a tumour has been 
initiated folate restriction is more important. This dual modulatory role of folate may be of 
even greater influence in an impaired DNA mismatch repair pathway as found in Lynch 
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syndrome patients. In this case folate supplementation may be particularly beneficial or 
deleterious depending upon any early tumour development.  
7. Haemochromatosis HFE gene polymorphisms 
The role of high body iron levels in modifying the risk of colorectal cancer has been 
investigated by several groups but remains unclear [126 – 130]. The genetic iron overload 
disorder hereditary haemochromatosis (HH) is characterised by high iron indices and 
progressive parenchymal iron overload and occurs due to a problem in restricting iron 
uptake (reviewed in [131- 133]. While clear associations have been established between 
haemochromatosis and liver disease, studies investigating the correlation between 
haemochromatosis and other pathologies have yielded conflicting results [134 – 137].  
The primary cause of classical HH has been ascribed to SNPs in the HFE gene, in particular 
the 845G>A SNP which results in the substitution of a tyrosine residue for a cysteine at 
position 282 (C282Y) and is present in 10-15% of individuals of northern European descent. 
The more common but less penetrant 163C>G SNP (H63D) is present in 15-30% of 
individuals [131, 136 – 142]. A longitudinal also study has demonstrated that up to 30% of 
men and 1% of women homozygous for the C282Y polymorphism develop iron overload 
that subsequently manifests as a disease phenotype [143]. The risk of developing colorectal 
cancer increased 3-fold in C282Y homozygotes when compared to matched controls without 
the mutation [144].  
A number of other epidemiological studies have also investigated the impact of HFE 
genotype on colorectal cancer risk, with mixed results [145 -148]. Most studies exploring the 
link between HFE genotype and the risk of developing colorectal cancer have approached 
the problem by selecting subjects diagnosed with colorectal cancer and comparing the 
frequency of HFE polymorphisms to matched controls.  
In regards to Lynch syndrome and the potential influence of disease risk one study has been 
reported suggesting that homozygosity of the HFE H63D mutation may act as a modifier, 
increasing the risk of developing CRC. In addition, there was evidence for earlier CRC onset 
age in H63D homozygotes [24]. The results of this study suggest that the median age of 
disease onset could be as much as 6 years earlier in H63D homozygotes (who represent 
around 2.5% of the Australian and Polish general populations).  
While these findings will require substantiation in other populations, they support a 
possible relationship between iron dysregulation and colorectal cancer risk. While 
mechanisms cannot be established by a genetic epidemiological study of this nature, it 
appears likely that iron is involved, in view of the roles of the HFE gene in iron metabolism, 
the previously reported effects of H63D homozygosity on iron status [149] and existing 
evidence that iron status can modify CRC. Since iron levels in haemochromatosis patients 
can usually be maintained at normal levels through phlebotomy and regulating factors such 
as diet, this might have the potential to substantially reduce colorectal cancer risks or delay 
onset by several years in people with HNPCC-associated MMR gene mutations.  
However the possibility of other mechanisms not directly reflecting abnormal body iron 
status cannot be ruled out. Homozygosity of the H63D polymorphism increases the risk of 
the neurodegenerative brain disease amyotrophic lateral sclerosis in the absence of apparent 
effects of C282Y polymorphism [150 – 152], suggesting that in some tissues the H63D 
mutation might have pathological consequences that are not directly related to whole body 
iron status. It will be important to validate the findings on H63D and also to investigate the 
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effects of C282Y homozygosity in larger HNPCC samples, preferably in conjunction with 
information on patient iron status, to determine the mechanisms involved and the role of 
iron. 
While this is the first time that the H63D polymorphism has been specifically associated 
with HNPCC, there is some previous evidence for association of both the H63D and the 
C282Y polymorphism with colorectal cancer in general [147, 148]. Power has limited past 
studies, as the homozygous and compound heterozygous mutations that have been 
associated with the greatest increases in iron loading and potentially the highest disease 
risks, are relatively rare. For this reason, some studies have analysed all HFE mutation 
genotypes as a single group, which may dilute observed effects. Although past 
epidemiological studies of HFE genotype and colorectal cancer risk have had mixed results, 
an American study of 475 colorectal cancer case patients and 833 control subjects found an 
odds ratio of 1.4 for participants with any HFE mutation after adjustment for a range of 
factors including age, gender and total iron intake [148]. The increased risk predominantly 
occurred in the quartile with greatest dietary iron intakes. In addition, a recent study of a 
large Australian sample has found that homozygosity for the C282Y SNP is associated with 
a three-fold increase in the risk of developing colorectal cancer in men [144]. This suggests 
that the effects of HFE on colorectal cancer may not be limited only to MMR gene mutation 
carriers, although such effects may be stronger when both types of mutation are present 
simultaneously. 
Heterozygosity for either the H63D or C282Y SNP does not appear to have any modifying 
effect in either the Australian or Polish samples, although it is possible that small effects 
may be detectable with very large samples. While heterozygosity for C282Y or H63D has 
been reported to have a range of effects in other diseases, reviewed in [153], these genotypes 
are not usually associated with significant changes in iron parameters [26, 154 – 156]. For 
these reasons, for our final analyses it was considered more appropriate to compare mutant 
homozygotes to combined heterozygotes and wildtype homozygotes, as is usually done in 
most studies of HFE gene SNPs. However, while this was effective in revealing the potential 
modifying effect of H63D homozygosity on HNPCC development, we were not able to do 
this for the C282Y SNP, due to its relative rarity and the lack of C282Y homozygotes in the 
samples. Stronger modifying effects may occur in C282Y homozygotes or C282Y/H63D 
compound heterozygotes, as it is well established that iron indices are increased most in 
individuals with these genotypes, reviewed in [131, 132, 157].  
Gender affects both the onset age and site of first tumour manifestation in HNPCC. In 
females, the age of onset of colorectal cancer is delayed 5 to 10 years when compared to 
males [158]. Gender is also a factor in the manifestation of iron loading as a result of HFE 
genotype, affecting males much earlier in life than females [159]. In a larger sample it is 
possible that HFE genotype may show a contribution to the earlier onset of CRC in males 
when compared to females.  
8. Candidate polymorphisms not associated with disease risk 
Not all polymorphisms which have been associated with hereditary disease have 
remained consistently significant across cohorts. An example is the delta DNMT3b SNP 
which was reported to have a significant association in a cohort of participants in the 
United States [160]. DNMT3B has been identified as a candidate in disease modifying risk 
due to its role in methylation. DNA methylation is regulated by a family of DNA 
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methyltransferases (DNMTs), of which three active forms (DNMT1, DNMT3A and 
DNMT3B) have been identified in mammalian cells [161]. It has been reported that an 
increase in DNA methyltransferase enzyme activity of the DNA methyltransferases 
DNMT1, and DNMT3A and DNMT3B, is elevated in several types of disease including 
leukemia, prostate, lung, breast and endometrial cancers [162 -165]. A polymorphism 
located within DNMT3b has been reported to influence enzyme expression through 
altering promoter activity. It has been suggested that in in vitro assays the C>T variant 
could lead to an increase of promoter activity of up to 30% [161]. Using a study group of 
over 400 individuals, no association was observed between age of onset and DNMT3b 
genotype in an Australian and Polish Lynch syndrome cohort. The failure to confirm the 
potential modifying influence of a polymorphism in one population compared to another 
could be simply due to insufficient numbers of test subjects. If a polymorphism is an effect 
modifier its response should be similar no matter what population is examined even 
though it may not reach statistical significance. In the case of the delta DNMT3b SNP no 
such trend was observed. The Australian/Polish study group was approximately three 
times larger than the participants of a previous study [160] and the most likely 
explanation for the difference in results is a type 1 error. Notwithstanding, it is worth 
noting that it does not rule out the possibility that DNMT3b expression may be associated 
with Lynch syndrome disease expression. Different isoforms of DNMT3b exist therefore 
expression levels of these may vary influencing disease risk. Numerous other 
polymorphisms have also been reported in the functional domains of DNMT3b which 
could also alter methylation status and thereby alter disease risk.  
Genes involved in DNA repair have also been prime candidates in the search for modifying 
effects due to their important role in the cell cycle. Polymorphisms located within genes 
involved in this process have been widely reported to be associated with cancer 
susceptibility in an extensive range of malignancies that include CRC. For one combined 
cohort (Australian and Polish Lynch syndrome patients), eight common polymorphisms 
were selected across several genes involved in the DNA repair pathway including BRCA2, 
hMSH3, Lig4, hOGG1 and XRCC 1, 2 and 3, which had not previously been assessed for 
disease risk in Lynch syndrome. When considered separately conflicting data were 
identified in the two populations. Cox regression modelling indicated a significant 
protective effect in Polish participants for both polymorphisms hMSH3 A>G (rs26279) and 
XRCC2 G>A (rs1799793). This finding was somewhat contradictory as the homozygote form 
of both rs26279 and rs1799793 have been previously weakly associated with an increased 
risk of CRC and bladder cancer respectively [166, 167]. Two points need to be taken into 
account in interpreting this data. First, since multiple tests were undertaken in evaluating 
the possible influence of DNA repair gene polymorphisms a correction for multiple testing 
must be undertaken to ensure that any observed result is not due to a chance association; 
second, population stratification may adversely affect result outcome but is less likely 
(Reeves et al. 2011 [168]. Differences in the probabilities of an association with the age of 
disease onset in relation to DNA repair gene polymorphisms occurring in small study 
groups is more likely to be a result of a type 1 or 2 statistical error and can be overcome by 
undertaking an appropriate power calculation to determine the expected power to detect an 
association. Furthermore, statistical correction (such as Bonferroni) is required especially 
where multiple testing is undertaken although some types of correction are somewhat 
conservative and could remove an association where one exists.  
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9. Summary 
There have been a number of studies that demonstrate the role of modifying genes that 
influence disease risk in Lynch Syndrome. Many studies have been undertaken that have 
failed to identify a range of candidate modifying genes as a result of studies being too small 
in size to provide robust statistical results. Nevertheless, there is a growing body of evidence 
that suggests modifying genes do influence disease risk in Lynch Syndrome and some of 
these are of particular interest as they suggest potential avenues by which disease risk can 
be modulated.  
The role of genome wide association studies in identifying new agnostic modifier genes is 
currently generating special interest and at this point two studies have reported intriguing 
associations that correlate well with disease risk. It remains to be seen if such associations 
can be verified in larger populations. The use of genome wide data or even target 
assessment of several thousand potential modifiers is fraught with difficulties not the least 
of which is the available population size and the number of individual SNPs analysed.  
Despite the difficulties encountered in identifying polymorphic modifier genes, their role in 
improving disease risk assessment is becoming clearer and the search for those that can 
make for individualised patient care will continue. 
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